glp-1 osteoporosis AAOS | A new study presented at #AAOS2026 revealed use may be linked to a 29% higher risk of after five years. As use of GLP-1 weight loss drug study

What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency

The fatigue management guide includes strategies for maintaining energy levels during treatment that apply to sexual energy as well

Clinical trials show Saxendas potential for substantial weight loss, with participants losing up to 10% of their body weight in a year when combined with lifestyle changes like dietary adjustments and regular exercise

Since no significant trauma was involved in this study, only a brief muscle twitch (restricted to the stimulated limb) was expected

IBS patients are also more likely to co-morbid with mood disorders like anxiety and depression (8, 9)

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials